Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-national, Phase III, Efficacy and Safety Study of Inhaled Formoterol 4.5 μg and 9 μg Twice Daily in Japanese and European Patients With Chronic Obstructive Pulmonary Disease (COPD)
Brief Summary: The purpose of this study is to show the efficacy and safety of formoterol for the maintenance treatment of patients with COPD compared with placebo in patients in Japan and in European countries during 12 weeks.


Options:
A: Intervention Type: DRUG; Name: Formoterol; Assigned to Arm(s): N/A
B: Arm Label: F 4.5 bid; Type: EXPERIMENTAL; Interventions: Drug: Formoterol Turbuhaler® 4.5mg | Arm Label: F 9.0 bid; Type: EXPERIMENTAL; Interventions: Drug: Formoterol Turbuhaler® 9 mg | Arm Label: PBO; Type: PLACEBO_COMPARATOR; Interventions: Drug: Turbuhaler® placebo | Intervention Type: DRUG; Name: Formoterol Turbuhaler® 4.5mg; Assigned to Arm(s): F 4.5 bid | Intervention Type: DRUG; Name: Formoterol Turbuhaler® 9 mg; Assigned to Arm(s): F 9.0 bid | Intervention Type: DRUG; Name: Turbuhaler® placebo; Assigned to Arm(s): PBO
C: Arm Label: Indacaterol 150 µg (Continued Into Stage 2); Type: EXPERIMENTAL; Interventions: Drug: Indacaterol, Drug: Placebo to Indacaterol, Drug: Placebo to Formoterol | Arm Label: Indacaterol 300 µg (Continued Into Stage 2); Type: EXPERIMENTAL; Interventions: Drug: Indacaterol, Drug: Placebo to Indacaterol, Drug: Placebo to Formoterol | Arm Label: Tiotropium 18 µg (Continued Into Stage 2); Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium (18 µg o.d.) | Arm Label: Placebo (Continued Into Stage 2); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to Indacaterol, Drug: Placebo to Formoterol | Arm Label: Indacaterol 75 µg (Not Continued into Stage 2); Type: EXPERIMENTAL; Interventions: Drug: Indacaterol, Drug: Placebo to Indacaterol, Drug: Placebo to Formoterol | Arm Label: Indacaterol 600 µg (Not Continued Into Stage 2); Type: EXPERIMENTAL; Interventions: Drug: Indacaterol, Drug: Placebo to Formoterol | Arm Label: Formoterol 12 µg (Not Continued Into Stage 2); Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol (12 µg b.i.d.), Drug: Placebo to Indacaterol | Intervention Type: DRUG; Name: Indacaterol; Assigned to Arm(s): Indacaterol 150 µg (Continued Into Stage 2), Indacaterol 300 µg (Continued Into Stage 2), Indacaterol 600 µg (Not Continued Into Stage 2), Indacaterol 75 µg (Not Continued into Stage 2) | Intervention Type: DRUG; Name: Formoterol (12 µg b.i.d.); Assigned to Arm(s): Formoterol 12 µg (Not Continued Into Stage 2) | Intervention Type: DRUG; Name: Tiotropium (18 µg o.d.); Assigned to Arm(s): Tiotropium 18 µg (Continued Into Stage 2) | Intervention Type: DRUG; Name: Placebo to Indacaterol; Assigned to Arm(s): Formoterol 12 µg (Not Continued Into Stage 2), Indacaterol 150 µg (Continued Into Stage 2), Indacaterol 300 µg (Continued Into Stage 2), Indacaterol 75 µg (Not Continued into Stage 2), Placebo (Continued Into Stage 2) | Intervention Type: DRUG; Name: Placebo to Formoterol; Assigned to Arm(s): Indacaterol 150 µg (Continued Into Stage 2), Indacaterol 300 µg (Continued Into Stage 2), Indacaterol 600 µg (Not Continued Into Stage 2), Indacaterol 75 µg (Not Continued into Stage 2), Placebo (Continued Into Stage 2)
D: Intervention Type: DRUG; Name: Salmeterol 50mcg/ Fluticasone Propionate 500mcg; Assigned to Arm(s): N/A

Answer: B